Results 51 to 60 of about 4,655,222 (236)

Sex Differences in Oral Anticoagulation Therapy in Patients Hospitalized With Atrial Fibrillation: A Nationwide Cohort Study

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2023
Background Important disparities in the treatment and outcomes of women and men with atrial fibrillation (AF) are well recognized. Whether introduction of direct oral anticoagulants has reduced disparities in treatment is uncertain.
Kuan Ken Lee   +14 more
doaj   +1 more source

7-Fluoroindazoles as Potent and Selective Inhibitors of Factor Xa

open access: yes, 2016
We have developed a novel series of potent and selective factor Xa inhibitors that employ a key 7-fluoroindazolyl moiety. The 7-fluoro group on the indazole scaffold replaces the carbonyl group of an amide that is found in previously reported factor Xa ...
Tianbao Lu (2457745)   +14 more
core   +1 more source

Dysregulation of the MACF1‐Rab14/KIF16B‐FGFR Vesicular Trafficking Axis Skews MSC Lineage Commitment in Glucocorticoid‐Induced Osteoporosis

open access: yesAdvanced Science, EarlyView.
Under normal conditions, MACF1 interacts with Rab14 and facilitates KIF16B‐mediated FGFR vesicle trafficking along microtubules to the plasma membrane, thereby supporting BMSC differentiation. In contrast, chronic GC exposure suppresses MACF1 expression, disrupting this transport and causing intracellular FGFR retention, which blunts osteogenic ...
Peihong Su   +14 more
wiley   +1 more source

SR‐A3 Promotes USP18‐Mediated deISGylation of STING to Protect Against Myocardial Ischemia‐Reperfusion Injury

open access: yesAdvanced Science, EarlyView.
MI/RI is a major clinical challenge with high morbidity and mortality. This study demonstrates that SR‐A3 expression is downregulated in MI/RI, and its deletion exacerbates damage via the USP18/ISG15/STING axis, revealing SR‐A3 as a potential therapeutic target.
Yufei Han   +24 more
wiley   +1 more source

SPECIFIC ANTIDOTES TO NEW ORAL ANTICOAGULANTS

open access: yesАтеротромбоз, 2016
Safety profiles of the novel oral anticoagulants (NOAC) (rivaroxaban, apixaban, edoxaban,  dabigatran) are better than that of warfarin. However, the risk (including lifethreatening) of bleeding  is no less than 2.3–3.1% per year.
O. O. Shakhmatova
doaj   +1 more source

FOXP1 Knockdown Reprograms Th9 CAR‐T Cells to Overcome Antigen Escape

open access: yesAdvanced Science, EarlyView.
FOXP1 knockdown enhances Th9 CAR‐T cell function by promoting IL‐9 production, effector activation, and reduced exhaustion. Reprogrammed Th9 CAR‐T cells strengthen direct tumor killing and activate endogenous antitumor immunity through dendritic cells and CD8+ T cells, thereby suppressing both antigen‐positive and antigen‐loss tumor growth and ...
Yihan Zhu   +14 more
wiley   +1 more source

Non‐Invasively Quantitative Raman Imaging for Calculation of Lymphatic Transport Kinetics of Micelles in Mice

open access: yesAdvanced Science, EarlyView.
Non‐invasively quantitative Raman imaging with stacking‐induced charge transfer‐enhanced Raman scattering (SICTERS) enables accurate measurement of concentrations and pharmacokinetic modeling of lymphatic transport of micelles in mice. This platform allows dynamic analysis of nanoparticle transport and underpins the design of effective lymph node ...
Yunlu Li   +6 more
wiley   +1 more source

Hybrid Metal–Organic Framework‐Derived Dual Active Site Catalysts Enabling Surface‐Enriched Cathode and Modified Zinc Anode for Long‐Life Zinc–Air Batteries

open access: yesAdvanced Science, EarlyView.
This work demonstrates the implementation of MOF‐assisted anode and cathode materials for prolonged cycling of zinc‐air batteries with strong redox capability and structural stability. ABSTRACT The surface modification of zinc anodes and the development of effective cathode dual‐functional oxygen electrocatalysts remain of paramount interest for ...
Ramasamy Santhosh Kumar   +7 more
wiley   +1 more source

Mechanistic Basis for the Differential Effects of Rivaroxaban and Apixaban on Global Tests of Coagulation

open access: yesTH Open, 2018
Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim   +7 more
doaj   +1 more source

New Hybrid Tetrahydropyrrolo[3,2,1-ij]quinolin-1-ylidene-2-thioxothiazolidin-4-ones as New Inhibitors of Factor Xa and Factor XIa: Design, Synthesis, and In Silico and Experimental Evaluation

open access: yesMolecules, 2023
Despite extensive research in the field of thrombotic diseases, the prevention of blood clots remains an important area of study. Therefore, the development of new anticoagulant drugs with better therapeutic profiles and fewer side effects to combat ...
Nadezhda P. Novichikhina   +12 more
doaj   +1 more source

Home - About - Disclaimer - Privacy